---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-052642"
form_type: "8-K"
ticker: "AZTA"
cik: "0000933974"
company_name: "Azenta, Inc."
filed_at: "2026-08-04T20:32:44+00:00"
generated_at: "2026-08-04T20:34:39.172192+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Azenta Reports Q3 Fiscal 2026 Revenue of $161M, Up 12% YoY

## Summary
- Revenue from continuing operations was $161M, up 12% year over year; organic growth was 9%.
- Sample Management Solutions revenue rose 14% to $88M; Multiomics revenue rose 10% to $73M.
- Diluted EPS from continuing operations was ($0.03); total diluted EPS was $0.05, compared to ($1.05) a year ago.
- Adjusted EBITDA from continuing operations was $18.5M, with margin of 11.4%.
- Sale of B Medical Systems closed on July 1, 2026; results reported as discontinued operations.

## SEC filing metadata
- accession: 0001628280-26-052642
- form_type: 8-K
- ticker: AZTA
- cik: 0000933974
- company_name: Azenta, Inc.
- filed_at: 2026-08-04T20:32:44+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/933974/000162828026052642/0001628280-26-052642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/933974/000162828026052642/azta-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-052642
- JSON: https://secwatch.observer/filing/0001628280-26-052642.json
- Plain text: https://secwatch.observer/filing/0001628280-26-052642.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.